Financial Snapshot

Revenue
$29.11M
TTM
Gross Margin
55.65%
TTM
Net Earnings
-$827.0K
TTM
Current Assets
Q3 2023
Current Liabilities
Q3 2023
Current Ratio
11.94%
Q3 2023
Total Assets
Q3 2023
Total Liabilities
Q3 2023
Book Value
-$36.78M
Q3 2023
Cash
Q3 2023
P/E
-27.08
Mar 20, 2024 EST
Free Cash Flow
-$2.904M
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Selling, General & Admin Expense

Research & Development

No data

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

No data

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

Interest & Other Expense/Income

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

No data

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $22.394 Million

About Unrivaled Brands, Inc.

Unrivaled Brands, Inc. is a holding company, which engages in the retail, cultivation, and production of medical cannabis and agricultural products. The company is headquartered in Santa Ana, California and currently employs 145 full-time employees. The company went IPO on 2011-02-10. The firm is engaged in providing medical and adult use cannabis products. The firm offers Korova, a brand of high potency products across multiple product categories, available in California, Oregon, Arizona, and Oklahoma. The company operates through two segments, namely Cannabis Retail and Cannabis Cultivation and Distribution. Cannabis Retail includes cannabis-focused retail, both physical stores and non-store front delivery. Cannabis Cultivation and Distribution includes cannabis cultivation, production, and distribution operations Either independently or in conjunction with third parties, the Company operates medical marijuana retail and adult use dispensaries and cultivation and production facilities in California. The company operates four cannabis dispensaries in California: People's in Santa Ana, The Spot in Santa Ana, Blum in Oakland, and Blum in San Leandro.

Industry: Retail-Miscellaneous Retail Peers: Ampio Pharmaceuticals, Inc. cbdMD, Inc. PLx Pharma Winddown Corp. Evofem Biosciences, Inc. Jaguar Health, Inc. JOHNSON & JOHNSON VYNE Therapeutics Inc. Pulmatrix, Inc. WEED, INC. Virpax Pharmaceuticals, Inc.